![Nerissa Kreher](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Nerissa Kreher
Directeur/Bestuurslid bij REZOLUTE, INC.
Vermogen: 619 372 $ op 31-05-2024
Profiel
Nerissa C.
Kreher is currently an Independent Director at Rezolute, Inc. She previously held positions as the Head of Medical Affairs and Clinical Development at Alexion Pharmaceuticals, Inc., Zafgen, Inc., EMD Serono, Inc., and Shire Human Genetic Therapies, Inc. She also served as the Chief Medical Officer at Avrobio, Inc., Tiburio Therapeutics, Inc., and is currently the Chief Medical Officer at Entrada Therapeutics, Inc. Dr. Kreher obtained a doctorate degree from East Carolina University, a graduate degree from Indiana University, an MBA from Northeastern University, and undergraduate degrees from The University of North Carolina at Chapel Hill and The University of North Carolina at Charlotte.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ENTRADA THERAPEUTICS INC
0.12% | 06-09-2023 | 40 037 ( 0.12% ) | 619 372 $ | 31-05-2024 |
REZOLUTE, INC.
-.--% | 18-03-2024 | 0 ( -.--% ) | - $ | 31-05-2024 |
Actieve functies van Nerissa Kreher
Bedrijven | Functie | Begin |
---|---|---|
REZOLUTE, INC. | Directeur/Bestuurslid | 02-03-2021 |
Eerdere bekende functies van Nerissa Kreher
Bedrijven | Functie | Einde |
---|---|---|
ENTRADA THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-02-2024 |
Tiburio Therapeutics, Inc.
![]() Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Hoofd Techniek/Wetenschap/O&O | 01-10-2020 |
TECTONIC THERAPEUTIC, INC. | Hoofd Techniek/Wetenschap/O&O | 17-12-2018 |
LARIMAR THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-07-2016 |
Shire Human Genetic Therapies, Inc.
![]() Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Nerissa Kreher
The University of North Carolina at Charlotte | Undergraduate Degree |
East Carolina University | Doctorate Degree |
Indiana University | Graduate Degree |
Northeastern University | Masters Business Admin |
The University of North Carolina at Chapel Hill | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
REZOLUTE, INC. | Health Technology |
ENTRADA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Zafgen, Inc.
![]() Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
Avrobio, Inc.
![]() Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
Tiburio Therapeutics, Inc.
![]() Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
EMD Serono, Inc.
![]() EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
Shire Human Genetic Therapies, Inc.
![]() Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | Health Technology |